Cosmo N.V. formerly known as COSMO Pharmaceuticals N.V. is an Ireland based pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases, dermatology, and healthtech. Its development pipeline includes Distal Ulcerative Colitis, Bile Acid Diarrhea, Solid Tumors, and AI Augmented Endoscopy. The Company's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, which is used for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which is used for the treatment of travelers’ diarrhea (TD); Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy, and Winlevi, which is used for the treatment of acne. It also develops medical devices to assist with clinical decision-making.
Back to dashboard
Company Information
About this company
Key people
Alessandro Della Cha
Non-Executive Chairman of the Board
Nhan Ngo Dinh
President - Cosmo Intelligent Medical Devices, Member of the Management Board
Dominika Spilarova
Chief Strategy Officer, Member of the Management Board
Mauro Severino Ajani
Non-Executive Director
John O'Dea
Non-Executive Director
Silvana Perretta
Non-Executive Director
Maria Grazia Roncarolo
Non-Executive Director
Giovanni Di Napoli
Chief Executive Officer, Executive Director, Member of the Management Board
Svetlana Sigalova
Chief Financial Officer, Member of the Management Board
Silvia Miliani
Chief Human Resources Officer
Niall Donnelly
Executive Vice President - Corporate Governance and Chief Sustainability Officer, Executive Director, Member of the Management Board
Luigi Longo
Chief Scientific Officer, Member of the Management Board
Federico Sommariva
Chief Legal Counsel
Andrea Cherubini
Chief Artificial Intelligence Officer, Member of the Management Board
Egle Gedrimaite
Member of the Management Board, Head - Global Business Development
Click to see more
Key facts
- Shares in issue17.54m
- EPICCMHC
- ISINNL0011832936
- LocationIreland
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capCHF 902.25m
- Employees365
- ExchangeSIX Swiss Exchange
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.